ProQR Therapeutics (PRQR) Debt to Equity (2013 - 2025)

ProQR Therapeutics has disclosed Debt to Equity across 13 years of filings, most recently posting $0.1 for Q4 2025.

• Debt to Equity for Q4 2025 came in at $0.1, up 90.72% year-over-year; the trailing twelve-month figure through Dec 2025 was $0.1 (up 90.72% YoY), and the FY2025 annual result was $0.1, up 90.72% from the prior year.
• Debt to Equity came in at $0.1 for Q4 2025 at ProQR Therapeutics, up from $0.05 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.43 in Q2 2022 to a low of $0.05 in Q4 2024.
• The 5-year median for Debt to Equity is $0.1 (2022), against an average of $0.17.
• Across the five-year window, Debt to Equity jumped 200.89% in 2022 and tumbled 84.04% in 2023, its largest moves.
• ProQR Therapeutics' Debt to Equity stood at $0.39 in 2021, then sank by 73.72% to $0.1 in 2022, then gained by 2.12% to $0.1 in 2023, then tumbled by 50.11% to $0.05 in 2024, then surged by 90.72% to $0.1 in 2025.
• The last three Debt to Equity figures came in at $0.1 (Q4 2025), $0.05 (Q4 2024), and $0.1 (Q4 2023), per Business Quant data.